Procalcitonin in Early Antibiotic Interruption in Patient With Bacterial Pulmonary infeCtion and Acute Heart Failure

Heart Failure Clinical Trial

— EPICAD  

Official title:

Evaluation of Procalcitonin in the Early Antibiotic Therapy Interruption in Patient With Bacterial Pulmonary infeCtion and Decompensated Acute Heart Failure

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02787603
• Other study ID #: PSInCor-Procalcitonin Clinical
• Status: Completed
• Phase: N/A
• First received: May 25, 2016
• Last updated: June 5, 2017
• Start date: January 2015
• Est. completion date: April 2017

Study information

• Verified date: January 2017
• Source: University of Sao Paulo General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Introduction: Acute Heart Failure is frequently decompensated by pulmonary infection, but the diagnosis of pulmonary infection sometimes is difficult in these patients due to similar signals and clinical symptoms in both pathologies. Furthermore, when it is possible the diagnosis of pulmonary infection, physicians may have difficult to determine etiology and delaying antibiotic therapy. Procalcitonin (PCT) have been used like a biomarker to determine the period of use of antibiotics in patients with acute respiratory infections. It is specific for bacterial infections and it have showed as a marker of severity infection and may help to determine interruption period of antibiotic therapy in a safety way for the patient. Aim: Evaluate levels of PCT related to interruption of antibiotics in patients with decompensated acute heart failure (DAHF) with suspected bacterial pulmonary infection. Methods: In this pilot project will be included around 100 patients, randomized in two groups: group A (PCT levels may guide the interruption of antibiotic at day 5) or group B (antibiotic period will be determined by the physician without the knowledge of PCT levels). Will be collected laboratorial and clinical data at days 0,3 and 5. Both groups will be compared to evaluate PCT levels and total period of antibiotic therapy, hospitalization and readmission in 30 days. This study will determine the sensibility/specificity of PCT in patients with DAHF.

Description:

It is a single-center study, randomized, controlled, prospective cohort and interventional not blind. DAHF diagnosis will consider symptoms, physical examination, x ray and other image methods and BNP ou NTproBNP levels. Pulmonary infection diagnosis will "Infectious Disease Society of America / American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults" criteria, that include fever, cough, sputum, pleuritic pain, positive pulmonary image and physical examination. PCT and NTproBNP levels will be measured in miniVIDAS® (bioMérieux Clinical Diagnostics, France). Statistics includes descriptive analysis. Parametric data will be evaluated using T test and non parametric data with Mann-Whitney-Wilcoxon test. Multivariative analysis related to diagnosis, mortality and morbidity will be performed by Cox regression model. Sensibility and specificity will be calculated by ROC curve. Statistical significancy will be considered when p<0.05.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 46
• Est. completion date: April 2017
• Est. primary completion date: January 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• DAHF diagnosis and suspected pulmonary infection

• BNP = 500 pg/mL or NTproBNP = 450 pg/mL for patients until 50 years old.

• BNP = 500 pg/mL or NTproBNP = 900 pg/mL for patients with 51 - 75 years old.

• BNP = 500 pg/mL or NTproBNP = 1800 pg/mL for patients older than 75 years.

Exclusion Criteria:

• Antibiotic use (oral or endovenous) in the last 15 days;

• Acute coronary syndrome;

• Creatinine > 3,0 mg/dL or hemodialysis;

• Pregnancy;

• Second suspectec infection;

• Suspected pulmonary thromboembolism;

• cancer;

• myocarditis.

Related Conditions & MeSH terms

• Communicable Diseases
• Heart Failure
• Infection
• Pneumonia
• Pneumonia, Bacterial
• Respiratory Tract Infections

Intervention

Other:
• Interruption of antibiotic treatment due to PCT measurement
In group A at day 5, if the patient shows no clinical signs of infection and PCT levels < 0,25ng/mL OR PCT > 0,25 ng/mL AND 80% reduction in comparison with day 0 PCT levels, antibiotic will be interrupted. If there is a constant level or decrease less than 80% when compared day 0 or 5, there is no change in antibiotic treatment.

Locations

Country	Name	City	State
Brazil	Unidade Clínica de Emergência - Instituto do Coração InCor HCFMUSP	São Paulo	SP

Sponsors (2)

Lead Sponsor	Collaborator
University of Sao Paulo General Hospital	BioMérieux

Country where clinical trial is conducted

Brazil, 

References & Publications (5)

Bafadhel M, Clark TW, Reid C, Medina MJ, Batham S, Barer MR, Nicholson KG, Brightling CE. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest. 2011 Jun;139(6):1410- — View Citation

Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Régnier B, Brun-Buisson C, Chastre J, Wolff M; PRORATA trial group.. Use of procalcitonin to reduce patients' exposure to antib — View Citation

Maisel A, Neath SX, Landsberg J, Mueller C, Nowak RM, Peacock WF, Ponikowski P, Möckel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng LL, Daniels LB, Christenson RH, Potocki M, McCord J, Terracciano G, Hartmann O, Bergman — View Citation

Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med. 2011 Sep 22;9:107. doi: 10.1186/1741-7015-9-107. Review. — View Citation

Schuetz P, Kutz A, Grolimund E, Haubitz S, Demann D, Vögeli A, Hitz F, Christ-Crain M, Thomann R, Falconnier C, Hoess C, Henzen C, Marlowe RJ, Zimmerli W, Mueller B; ProHOSP Study Group.. Excluding infection through procalcitonin testing improves outcomes — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total period of antibiotic therapy		30 days
Secondary	hospitalization		30 days
Secondary	mortality		30 days
Secondary	PCT levels during antibiotic therapy		5 days